drugset
Drugs / NRD135S.E1
last change Aug 2025 re-read 3 minutes ago

NRD135S.E1

also known as NRD135s.E1, a small chemical entity for treatment of neuropathic pain

Small molecule

Developed for
diabetic polyneuropathy
Investigated by
Icahn School of Medicine at Mount Sinai · Massachusetts General Hospital · National Institute of Neurological Disorders and Stroke (NINDS) · New York University · Novaremed Ltd.

Trials 2

today NCT05480228 · Ph 2 NCT02345291 · Ph 2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05480228 Sep 2022 → Aug 2025 diabetic polyneuropathy Massachusetts General Hospital Completed No outcome recorded
Phase 2 NCT02345291 Apr 2015 → Jul 2016 diabetic polyneuropathy Novaremed Ltd. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2020-12-22 Novaremed Ltd. Novaremed receives Fast Track Designation from the FDA for NRD135S.E1 for treatment of Painful Diabetic Peripheral Neuropathy novaremed.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NRD135SE.1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480228 ↗
1

NCT02345291 ↗
Known as NRD135s.E1, a small chemical entity for treatment of neuropathic pain “NRD135s.E1, a small chemical entity for treatment of neuropathic pain” NCT05480228 ↗
Modality Small molecule “A small chemical entity” NCT02345291 ↗
Route Oral “once daily PO” NCT02345291 ↗